Human Genome Sciences ( HGSI) posted a narrower-than-expected loss after seeing a jump in revenue and lower costs in the third quarter.

Revenue was $5.9 million in the quarter, compared with $700,000 last year, an increase mostly thanks to milestone payments from GlaxoSmithKline ( GSK) for Human Genome's diabetes drug Albugon.

Overall, the Rockville, Md., biopharma company lost $54.4 million, or 42 cents a share, compared with a loss of $62.2 million, or 48 cents a share, a year earlier.

In the year-ago third quarter, the company took a charge of 5 cents a share for consolidating manufacturing facilities and for costs associated with the retirement of its former chairman and chief executive.

Shares of Human Genome were gaining 11 cents to $8.33 Tuesday.

More from Stocks

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

10 Stocks Goldman Sachs Thinks Will Crush the S&P 500's Performance in 2019

10 Stocks Goldman Sachs Thinks Will Crush the S&P 500's Performance in 2019

Dropbox Is the New Defensive Stock to Own With the Market Falling Apart

Dropbox Is the New Defensive Stock to Own With the Market Falling Apart

3 Warning Signs the Stock Market Could Collapse

3 Warning Signs the Stock Market Could Collapse